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ABSTRACT 
Parenteral dosage forms are one of the most commonly used pharmaceutical dosage forms in veterinary medicine, at the same time 
the combination therapy of multiple drug products is a common practice in this field. The aim of this research was to develop a high 
quality, stable solution that combines Florfenicol and Flunixin meglumine in a multidose injectable dosage form. Different organic 
solvents were tested to determine the optimal solvent for the active substances in the formulation. Citric acid was used in the 
formulation to overcome the problem of Flunixin instability and ethyl alcohol was incorporated in the formula in order to enhance 
syringeability and injectability of the solution. All prepared formulations were evaluated for their chemical and physical stabilities. 
The candidate formula showed good physical and chemical stability after two weeks of storage at both room temperature and 
accelerated conditions. Samples from three pilot scale batches were stored at accelerated stability conditions for 6 months and 
didn’t show any significant physical or chemical instability.   A generic parenteral solution drug product containing Florfen icol and 
Flunixin meglumine for veterinary use was successfully developed using mixture of organic solvents and excipients.  
Keywords: Florfenicol, Flunixin, parenteral, veterinary, formulation. 
 
INTRODUCTION 
arenteral term is used in pharmaceutics to describe 
drug products administered by injection, examples 
for this route include intravenous (IV), 
intramuscular (IM), subcutaneous (SC), intracardiac and 
intraspinal injections. The parenteral route is one of the 
most effective routes for drug administration especially in 
animals. There are various forms of pharmaceutical 
products that can be administered by this route such as 
solutions, emulsions and suspensions.1,2 
Veterinary parenteral dosage forms include aqueous 
organic solutions, oily solutions, emulsions, aqueous 
suspensions, oily suspensions, and sustained release 
implants. While, veterinary dosage forms frequently 
contain the same pharmaceutical ingredients that are 
used in human dosage forms, few of them contain active 
ingredients that are not used in humans and intended for 
animal use only. Examples of API's that have been 
developed specifically for animal use include some 
antimicrobial agents classified under sulfonamides, 
fluoroquinolones, macrolides, and chloramphenicol 
derivatives.3  
As in human drug products, the formulation of animal 
preparations require  fundamental knowledge in 
pharmaceutics, technology, dosage form design, 
pharmaceutical operations, quality control testing and in 
performing pre-formulation studies.4 
Florfenicol and flunixin meglumine is a multidose 
injectable solution, which contains 300 mg florfenicol and 
16.5 mg flunixin as flunixin meglumine per mL. 
This drug product combination is intended to treat bovine 
respiratory disease (BRD) associated with Pasteurella 
haemolytica, Pasteurella multocida, Histophilus somni, 
and Mycoplasma bovis, and to control BRD associated 
with pyrexia in beef and non-lactating dairy cattle.5,6  
There are many pharmaceutical companies, that produce 
veterinary medicines containing the antibacterial 
florfenicol injectable solution 7,8 or the anti-inflammatory 
flunixin meglumine injectable solution9–11, but the only 
product containing a combination of both APIs is Resflor 
Gold® injectable solution, the brand name is produced by 
Intervet/Merck Animal Health Company. 10,12 
Florfenicol is a phenicol antibiotic, classified under the 
amphenicol group of antibiotics, which includes 
chloramphenicol and thiamphenicol. It is a fluorinated 
derivative of thiamphenicol, with the chemical name 2,2- 
dichloro-N-1-(fluoromethyl)-2-hydroxy-2-[(methyl 
sulfonyl) phenyl] ethyl]-acetamide.13–15 The structure of 
florfenicol is shown in Figure 1. 
Florfenicol is a white or almost white crystalline powder, 
practically insoluble in water, soluble in acetone and 
DMF, soluble in ethanol (50 mg/mL), DMSO (100 mM), 
water (1.32 mg/mL, pH 7) 14 
Flunixin meglumine is cyclo-oxygenase inhibitor analgesic, 
a non-steroidal anti-inflammatory (NSAID). It is used in 
animals to reduce pain and inflammation associated with 
serious and chronic disorders of endotoxic or septic shock 
and mastitis. Flunixin meglumine is 2-[ [2-Methyl-3-
(trifluoromethyl) phenyl] amino] pyridine-3-carboxylic 
Development and Evaluation of Parenteral Solution containing Florfenicol and Flunixin 
Meglumine for Veterinary Use  
P 
Research Article 
Int. J. Pharm. Sci. Rev. Res., 52(2), September - October 2018; Article No. 07, Pages: 39-43                                            ISSN 0976 – 044X 
 
 
International Journal of Pharmaceutical Sciences Review and Research . International Journal of Pharmaceutical Sciences Review and Research 
Available online at www.globalresearchonline.net  
© Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited. 
. 
. 
Available online at www.globalresearchonline.net 
 
40 
acid, 1-deoxy-1- (methylamino)-D-glucitol.16–18 The 
structure of flunixin meglumine is shown in Figure 1. 
Flunixin meglumine is a white or almost white, crystalline 
powder, freely soluble in water and in methanol, 







Figure 1: Chemical structure of florfenicol and flunixin 
meglumine 
MATERIALS AND METHODS  
Instrumentation 
Climatic chamber KBF 240 Binder, Steam autoclave #1 
STE-18L MRC Ltd., Viscometer DV1MLVTJ0 Brookfield, 
Dionex-Ultimate 3000 HPLC system, equipped with LPG-
3400SD pump, WPS-3000SL autosampler, TCC-3000 
column oven, and DAD-3000 UV–VIS diode array 
detector. Chromeleon Data system Software (Version 
6.80 DU10A Build 2826 (171948)) was used for HPLC data 
processing and evaluation. The used of double distilled 
water was obtained from Aquatron equipment model A 
4000D. 
Chemicals and reagents  
Active ingredients (florfenicol and flunixin meglumine) 
were purchased from Sigma Aldrich. Florfenicol, Flunixin 
meglumine, N-methyl-2-pyrrolidone, Ethyl alcohol and 
Glycerol formal were donated by local Pharmaceutical 
Company. Propylene glycol was purchased from Dow 
Chemical Co. Polyethylene glycol 400 was purchased from 
OXITENO and Citric acid was purchased from Merck. The 
acetonitrile used was HPLC grade and water was obtained 
by double distillation. Other reagents such as phosphoric 
acid, hydrochloric acid, sodium hydroxide, and hydrogen 
peroxide were analytical grade and purchased from 
Merck and Sigma Aldrich. 
Pre-formulation 
Drug product characterization 
Before starting the experimental part, the critical quality 
attributes, the desired quality characteristics and 
properties of the finished product such as assay, sterility, 
stability, safety, viscosity and syringeability were all 
defined. 
The final formulation to be developed should contain 
florfenicol 300 mg per mL and flunixin meglumine 27.4 
mg per mL to give a 16.5 mg final concentration of  
flunixin in a mixture of different excipients. 
Selection of excipients 
Since the developed product is a parenteral solution, 
solubility of the active materials is critical. The use of 
solubilizing agents, antimicrobial preservative, acidifying 
agents, stabilizers, complexing agent and viscosity 
reducing agents were evaluated.  
Depending on literature survey, characterization of the 
two active materials and the knowledge of their 
physiochemical properties, a number of excipients were 
selected to perform formulation and to achieve the 
required final chemical, physical and microbiological 
properties of the developed drug product.  
Flunixin meglumine have a good solubility in water while 
florfenicol solubility is better in organic solvents such as 
N-methyl-2-pyrrolidone (NMP), polyethylene glycol and 
glycerol formal. Taking in consideration the two API's 
solubility, similar products containing florfenicol, NMP 
was determined to be the main solvent in this 
formulation; because it can dissolve not only florfenicol 
but also flunixin meglumine. 
Other solvents were investigated such as water, ethanol, 
propylene glycol (PG), glycerol formal (GF) and 
polyethylene glycol 400 (PEG). NMP was the candidate 
solvents constituting about 80% of the formulation. 
Ethyl alcohol (EA) and water were used to reduce the 
drug product viscosity to a suitable level that provides 
acceptable syringeability and injectability. Citric acid (CA) 
was used to stabilize Flunixin meglumine, while lactic acid 




During the study, the appearance of the product was 
checked visually, and was compared with the patented 
product. The viscosity was measured using a Brookfield 
viscometer DVI, spindle type # (LV-02) # 62. The tests 
were carried out at two rotation speeds, 50 and 100 rpm, 
at 25⁰C. 
Analytical assay development 
A preliminary chromatographic analytical method for 
determination of Florfenicol and Flunixin was developed 
and validated, as a stability indicating method, to 
evaluate the finished product during development and 
stability testing. The analytical validation study of the 
developed method has been published as a novel 
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The sterility of the developed product was tested using 
the membrane filtration method described in the United 
States Pharmacopeia (USP). 
Accelerated stability study 
The study was conducted in accordance with ICH 
guidelines regarding selection of batches, storage 
conditions testing frequency and acceptance criteria. 
Three pilot batches of the candidate formulation of the 
developed drug product were prepared for the study with 
the same strength as the product to be marketed and 
without any overage. A 100-mL amber glass vial (type-II) 
contained in a cardboard box was used as a primary 
packaging materials. 
Sufficient samples of each batch, in their final packaging, 
were stored at two controlled storage conditions and 
samples were periodically tested according to the testing 
program (Table 1)  
 
 
Table 1: Storage conditions and testing frequency 





40 C 75% 
0, 3, and 6 
months Normal 
conditions 
25 C 60% 
The physical, chemical and microbiological tests were 
performed in accordance with the testing frequency 
program.  
RESULTS AND DISCUSSION 
Formulation development 
Different formulation trials were prepared to determine 
the final formula and the best formulation procedure as 
summarized in Table 2. These formulations were 
prepared according to the quantities specified in the 
Table using different manufacturing procedures. The 
product was manufactured and filled using aseptic 
techniques in an aseptic environment.   
Table 2: Summary of formulation trials that were prepared to choose the final candidate formula and manufacturing 
procedure 
Material Flr Flx NMP PEG GF LA CA EA Water PG 
Unit g g mL mL mL mL g mL mL mL 
Formula (Quantities per 100 mL) 
FF1 30.0 2.74 30.0 20.0 18.0 0.0 0.0 0.0 0.0 15.0 
FF2 30.0 2.74 30.0 8.0 30.0 0.0 0.0 0.0 0.0 15.0 
FF3 30.0 2.74 30.0 8.0 15.0 0.0 0.0 0.0 15.0 15.0 
FF4 30.0 2.74 30.0 8.0 12.5 2.5 0.0 0.0 15.0 15.0 
FF5 30.0 2.74 30.0 8.0 20.0 0.0 0.0 0.0 10.0 15.0 
FF6 30.0 2.74 30.0 8.0 17.5 2.5 0.0 0.0 10.0 15.0 
FF7 30.0 2.74 30.0 8.0 10.0 0.0 0.0 20.0 0.0 15.0 
FF8 30.0 2.74 30.0 8.0 30.0 0.0 1.0 0.0 0.0 15.0 
FF9 30.0 2.74 30.0 8.0 10.0 0.0 1.0 20.0 0.0 15.0 
 
In formulas FF1 and FF2, Florfenicol and flunixin 
meglumine were dissolved completely in N-methyl-2-
pyrrolidone (NMP), then while mixing continuously, a 
mixture of about 80% glycerol formal (GF) and 
polyethylene glycol 400 (PEG) was added, this was 
followed by the addition of the other excipient in addition 
to  propylene glycol (PG). Finally, the total volume was 
accurately completed by GF. In trials FF3 to FF7 
Florfenicol and flunixin meglumine were dissolved 
completely in NMP, then while mixing a mixture of about 
80% GF and PEG was added followed by the addition of a 
mixture of water and PG, at the end the total volume was 
accurately completed by GF. 
In trials FF8 and FF9 Citric acid was completely dissolved 
in NMP. Flunixin meglumine was then added while mixing 
till completely dissolved, after that florfenicol was added 
and mixed until completely dissolved, other excipients 
were added during continuous mixing. The final drug 
product was filled in 100-mL amber glass vials, type II as 
the primary packaging material, each vial was closed with 
rubber stopper and aluminum cap, labeled and packaged 
in a well-designed and elegant cardboard carton box as 
secondary packaging material. 
The quality of the prepared trials was evaluated regarding 
chemical and physical properties. As a starting point, 
experiment FF1 was somewhat satisfactory except for the 
high viscosity of the solution. Modifications were 
necessary to decrease the viscosity, thus the amount of 
PEG was reduced as seen in formulation FF2, but this 
approach was not effective. The choice of incorporating a 
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viscosity decreasing agents in the formulation, such as 
water or ethyl alcohol, was used concurrently in 
experiments FF3, FF4, FF5, FF6 and FF7. A 15% of water 
was used in experiments FF3 and FF4 at two different pH 
values using lactic acid as acidifying agent, the viscosity 
was decreased but unfortunately, there was some 
turbidity in the solution after a few days of the 
preparation due to the precipitation of florfenicol. In 
experiments FF5 and FF6 the water percentage was 
reduced to 10%, the viscosity was good in both 
experiments but some precipitation occurred in 
experiment FF6 which had the acidic pH. Formulation FF5 
showed the best viscosity compared to other 
formulations that contained water. In experiment 
FF7where ethyl alcohol was used, the viscosity of the 
solution was better than that obtained by FF5; therefore, 
FF7 formula was selected for further evaluation and 
testing. 
Samples from experiment FF7 were analyzed and the 
assay of both florfenicol and flunixin were determined 
using the previously developed HPLC assay method, 
florfenicol results were acceptable but there was a 
significant loss in the flunixin assay. In experiment FF8, 
citric acid was used in the formulation to stabilize the 
flunixin meglumine, also it was used FF9 experiment in 
the presence of ethyl alcohol, and the two formulations 
had acceptable assay results for both florfenicol and 
flunixin. 
Formula FF9 showed the best results regarding the 
viscosity of the solution and the assay of the active 
materials, in consequence it was selected as the 
candidate formula. 
Formulations from FF9 were retained for a couple of 
weeks at room temperature for fast evaluation of stability 
before submitting it to the incubator for accelerated 
stability study. 
The obtained results of analysis were excellent for both 
physical appearance and chemical assay tests.   
Accelerated stability study 
Accelerated stability study was performed on three pilot 
batches of the candidate formula FF9 stored for 6 months 
at two storage conditions and tested frequently as 
recommended by ICH guidelines. The tested quality 
parameters assayed were; physical appearance, viscosity, 
and sterility.  
Results of the stability testing after 6 months, under 
different storage conditions, didn’t show any significant 
change as seen in Table 3, also no turbidity was found 
suggesting that the candidate formula FF9 is physically 
and chemically stable. This formulation was selected as 
the final formulation for the developed drug product 
Florfenicol and Flunixin meglumine injectable solution.    
Table 3: Results of the accelerated stability study 
BN Month 
Assay % 
Color Clarity Viscosity (mpa.s) Sterility 
Flr Flx 
Storage condition 1: 25°C/60% RH 
A 
0 99.3 99.0 Light yellow Clear 25.2 Sterile 
3 102.5 98.9 Light yellow Clear NA NA 
6 99.8 98.9 Light yellow Clear 29.4 Sterile 
B 
0 99.1 98.7 Light yellow Clear 25.8 Sterile 
3 102.4 98.9 Light yellow Clear NA NA 
6 99.6 99.4 Light yellow Clear 27.5 Sterile 
C 
0 99.7 98.9 Light yellow Clear 26.1 Sterile 
3 102.8 98.7 Light yellow Clear NA NA 
6 100.2 101.0 Light yellow Clear 28.7 Sterile 
Storage condition 2: 40°C/75% RH 
A 
0 99.3 99.0 Light yellow Clear 25.2 Sterile 
3 102.3 100.8 Light yellow Clear NA NA 
6 98.8 97.9 Light yellow Clear 29.7 Sterile 
B 
0 99.1 98.7 Light yellow Clear 25.8 Sterile 
3 102.3 101.3 Light yellow Clear NA NA 
6 98.6 97.3 Light yellow Clear 26.5 Sterile 
C 
0 99.7 98.9 Light yellow Clear 26.1 Sterile 
3 101.1 102.3 Light yellow Clear NA NA 
6 98.7 97.2 Light yellow Clear 28.6 Sterile 
Acceptance criteria ±5% of initial Light yellow Clear NA Sterile 
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A generic parenteral drug product containing Florfenicol 
and Flunixin meglumine, intended for veterinary use, was 
successfully developed using a mixture of organic solvents 
and excipients. The product showed excellent physical 
and chemical stability after storage under different 
conditions, as recommended by the official accelerated 
stability testing guidelines.  
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